Clinical trials: NSCLC Stage IIIB

Lung Cancer, Stage IIIb Lung Cancer

IPI-504 in NSCLC Patients With ALK Translocations

• Terminated
• Age: 18 years and older
• Phase 2
• Results posted

IPI-504 blocks a protein that is in cancer cells and is also in normal cells. This protein is called Heat Shock Protein-90 (Hsp90). Hsp90 helps protect certain other proteins from being destroyed by cells.

Conditions

Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer

Trial name

NCT01228435

Testing

IPI-504

Where

2 sites in United States

Volunteers

3 people

Sponsor

Massachusetts General Hospital